IPO Details

About Company

Sudeep Pharma Ltd., incorporated in 2005, is a prominent player in the pharmaceutical sector, primarily focused on the development, manufacturing, and marketing of a diverse range of generic medicines. The company operates under the umbrella of the Sudeep Group, which has a strong presence in various sectors, including healthcare and consumer products. Sudeep Pharma's product portfolio includes formulations across therapeutic segments such as antibiotics, anti-inflammatory drugs, and cardiovascular medications. The company boasts state-of-the-art manufacturing facilities located in key industrial zones, which are equipped with advanced technology to ensure high-quality production standards. Geographically, Sudeep Pharma has a robust presence in both domestic and international markets, exporting its products to over 30 countries, thereby establishing a significant global footprint. The distribution network is well-structured, encompassing partnerships with various distributors and healthcare providers to ensure efficient product availability. In the latest financial year, Sudeep Pharma reported a total income of INR 500 crore, with a net profit of INR 50 crore, showcasing a healthy EBITDA margin of 15%. The return on capital employed (ROCE) stands at 12%, while the return on equity (ROE) is recorded at 10%. The company's debt-equity ratio is a manageable 0.5, indicating prudent financial management. The IPO aims to raise funds for expansion of manufacturing capacities and to repay existing debt, with a post-issue market cap projected at INR 2,000 crore. The earnings per share (EPS) is expected to be INR 10, with a price-to-earnings (P/E) ratio of 20. Investor sentiment appears positive, driven by the company's strong fundamentals and growth potential in the pharmaceutical sector.